- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02709577
A Study of the GI Sleeve for the Treatment of Type 2 Diabetes
A Pilot Feasibility Sham Controlled Study of the GI Sleeve for the Treatment of Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study was designed as a randomized, single blind, sham controlled, pilot efficacy study of subjects with Type 2 diabetes enrolled at 2 centers in Santiago, Chile. Subjects were enrolled at a 2:1 ratio (EndoBarrier to sham). Following implantation or sham procedure, subjects were treated for 24 weeks or 52 weeks. Following explant, subjects were followed for an additional 8-12 weeks.
Subject evaluations included measurements of HbA1c, glucose, insulin, weight, changes in diabetic medications, and meal tolerance tests. Safety was monitored through the collection of clinical labs, physical assessments, endoscopy and adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years and < 55 years - Male or Female
- Patients with type 2 diabetes, treated for 10 years or less
- HbA1c level ≥ 7.0 and ≤ 10.0%
- Fasting glucose ≤ 240 mg/dl
- Patients taking metformin, sulfonylureas or thiazolidinediones (TZDs), either alone or in combination
- BMI > 30 and <50
- Patients willing to comply with study requirements
- Patients who have signed an informed consent form
- Women who are post-menopausal, surgically sterile, or on oral contraceptives for at least three months and who do not plan on becoming pregnant during the course of the study.
Exclusion Criteria:
- Patients taking oral medications to control their diabetes other than sulfonylureas, metformin or thiazolidinediones
- Patients diagnosed with type 1 diabetes mellitus or had a history of ketoacidosis
- Patients requiring insulin
- Patients with lab evidence of probable insulin production failure (fasting C peptide serum level < 1ng/ml)
- Patients with a weight loss of > 10 lbs within the three months of screening
- Patients requiring prescription anticoagulation therapy
- Patients with iron deficiency and iron deficiency anemia
- Patients with a history of abnormal pathologies of the GI tract
- Patients with known gallstones or kidney stones prior to implant
- Known infection at the time of implant
- Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
- Pregnant or has the intention of becoming pregnant in the next 12 months
- Patients with a history of active kidney stones
- Mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement or clinical trial
- Previous GI surgery that could affect the ability to place the sleeve or the function of the implant
- Patients unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
- H. pylori positive patients (Note: patients may be enrolled if they had a prior history and were successfully treated)
- Patients receiving weight loss medications such as Meridia and Xenical
- Family or patient history of a known diagnosis or pre-existing symptom of systemic lupus erythematous, scleroderma or other autoimmune connective tissue disorder
- Patients with Gastrointestinal Reflux Disease (GERD)
- Participating in another ongoing investigational clinical trial
- Patients taking corticosteroids or drugs known to affect gastrointestinal motility (such as reglan)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EndoBarrier Gastrointestinal Liner
Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
|
The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum.
The implant is fixed in place with the aid of a metal anchor.
The device is delivered via an endoscope.
The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
Other Names:
|
Experimental: Sham: endoscopy and standard of care
Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
|
Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c Values From Baseline Measurement
Time Frame: Baseline to 24 weeks or 52 weeks
|
Cohort A: Assessment of improvement in the glycemic control defined as a change in HbA1c values from baseline. Cohort B. Assessment of improvement in glycemic control defined as a change in HbA1c values of at least 0.5% from baseline. |
Baseline to 24 weeks or 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute Weight Change
Time Frame: 24 weeks or 52 weeks
|
24 weeks or 52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Leonardo Rodriguez Grunert, MD, Hospital Dipreca
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
-
University of Alabama at BirminghamActive, not recruitingType 2 Diabetes MellitusUnited States
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... and other collaboratorsCompletedType 2 Diabetes Mellitus
Clinical Trials on EndoBarrier Gastrointestinal Liner
-
GI DynamicsCompletedObesity | Type 2 DiabetesUnited Kingdom
-
GI DynamicsTerminatedObesity | Type 2 Diabetes
-
GI DynamicsCompleted
-
Imperial College LondonUniversity Hospital Southampton NHS Foundation Trust; National Institute for... and other collaboratorsUnknownDiabetes | Overweight and ObesityUnited Kingdom
-
GI DynamicsBiostatistical Consulting, Inc.Recruiting
-
GI DynamicsCompleted
-
Filip Krag KnopUniversity of CopenhagenCompletedObesity | Type 2 DiabetesDenmark
-
GI DynamicsCompleted
-
GI DynamicsCompleted